One of the further beneficial effects of empagliflozin, demonstrated in this study, is a significant reduction in the expression of transforming growth factor-Beta1 (TGF-Beta1), whose expression is significantly increased in the myocardium of the tested animals with diabetes. This evidence concerns the gene TGFB1 and diabetes mellitus.